Epoxide hydrolases (EH) are a component of every living thing. A 120 kDa dimer of two identical, 62.5 kDa monomers arranged in an anti-parallel manner makes up the mammalian soluble epoxide hydrolase (sEH). The liver, kidneys, brain, endothelium, and to a lesser extent other tissues, express it most prominently. Many disease states have significant components of inflammation and pain. Blood pressure, inflammation, and pain are all decreased by mammalian sEH inhibition. The down-regulation of COX2 transcription caused by NF-B, which results in less production of pro-inflammatory prostaglandins like PGE2 and PGD2, is a contributing factor in the anti-inflammatory activities of sEH inhibitors.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V51413 | (Rac)-EC5026 ((Rac)-BPN-19186) | 1809885-55-9 | (Rac)-EC5026 ((Rac)-BPN-19186) is an example of a potent soluble epoxy hydrolase (sEH) with a Ki of 0.06 nM. |
|
V11535 | AR-9281 | 913548-29-5 | AR-9281 is a novel and potent inhibitor of soluble epoxide hydrolase (s-EH) that can be potentially used for the treatment of hypertension and type 2 diabetes. |
|
V37609 | EC-5026 (BPN-19186) | 1809885-32-2 | EC5026 (BPN19186) is a novel, first-in-class, potent and orally bioabailable inhibitor of soluble Epoxide Hydrolase (sEH). |
|
V2720 | GSK2256294A | 1142090-23-0 | GSK2256294A (also known as GSK-2256294) is a novel, potent, selective inhibitor of recombinant human, rat and mouse sEH (Soluble epoxide hydrolase) (IC50 = 27 pM) with the potential to be used for endothelial dysfunction or abnormal tissue repair, such as diabetes, wound healing or COPD. |
|
V51410 | sEH inhibitor-1 | 1208549-68-1 | sEH Inhibitor-1 (Compound TCPU) is a potent surface-active soluble epoxide hydrolase (sEH) with IC50 of 0.4 and 5.3 nM in human and mouse, respectively. |
|
V79455 | sEH inhibitor-10 | sEH inhibitor-10 (compound 37) is a selective soluble epoxide hydrolase (sEH) inhibitor (IC50=0.5 μM). | |
|
V79775 | sEH inhibitor-11 | sEH inhibitor-11 (compound 35) is an inhibitor (blocker/antagonist) of sEH with IC50 of 0.3 μM. | |
|
V79776 | sEH inhibitor-12 | sEH inhibitor-12 (compound 34) is an inhibitor (blocker/antagonist) of sEH with IC50 of 0.7 μM. | |
|
V79454 | sEH inhibitor-13 | sEH inhibitor-13 (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor (antagonist) with IC50 of 0.4 μM. | |
|
V78351 | sEH inhibitor-16 | sEH inhibitor-16 is a soluble epoxide hydrolase (sEH) inhibitor (antagonist) with IC50 of 2 nM. | |
|
V74005 | sEH inhibitor-2 | 2816102-69-7 | sEH inhibitor-2 (Compound 5l) is an orally bioactive (predicted % absorption: 71.2-88.4%) soluble epoxide hydrolase (sEH) inhibitor (antagonist) with IC50 of 0.9 nM. |
|
V74006 | sEH inhibitor-4 | 2851838-08-7 | Intensive structural modifications led to the identification of compound B15 as a potent sEH inhibitor (antagonist) with IC50 of 0.03 ± 0.01 nM, which also contains soluble epoxide hydrolase (sEH) that can reduce inflammation and pain. |
|
V51409 | sEH inhibitor-7 | 340221-20-7 | sEH inhibitor-7 (compound c-2) is a soluble epoxide working enzyme (sEH) with IC50 of 0.15 μM (mouse sEH) and 6.2 μM (human sEH). |
|
V51411 | SWE-101 | 2376322-12-0 | SWE101 (compound 22 b) is a potent soluble epoxide buffered enzyme (sEH)-P coupler with IC50s of 4 μM and 2.8 μM for the dye sEH-P, respectively. |
|
V33532 | TPPU | 1222780-33-7 | TTPU is a soluble epoxide hydrolase (sEH) inhibitor with IC50 of 37 and 3.7 nM for monkey and human sEH, respectively. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
